HER-2: A biomarker at the crossroads of breast cancer immunotherapy and molecular medicine
Author:
Publisher
Wiley
Subject
Cell Biology,Clinical Biochemistry,Physiology
Reference81 articles.
1. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
2. Immunobiology of HER-2/ neu oncoprotein and its potential application in cancer immunotherapy
3. Vaccination against the HER-2/neu oncogenic protein.
4. Peptide-based vaccines for cancer immunotherapy
Cited by 28 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A liposome-based cancer vaccine for a rapid and high-titre anti-ErbB-2 antibody response;European Journal of Pharmaceutical Sciences;2020-09
2. Intratumor lactate levels reflect HER2 addiction status in HER2‐positive breast cancer;Journal of Cellular Physiology;2018-08-21
3. Discovery of new human epidermal growth factor receptor-2 (HER2) inhibitors for potential use as anticancer agents via ligand-based pharmacophore modeling;Journal of Molecular Graphics and Modelling;2015-09
4. Nano-pharmaceutical Formulations for Targeted Drug Delivery against HER2 in Breast Cancer;Current Cancer Drug Targets;2015-02-20
5. Vaccination with ErbB-2 peptides prevents cancer stem cell expansion and suppresses the development of spontaneous tumors in MMTV-PyMT transgenic mice;Breast Cancer Research and Treatment;2014-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3